Future research should prioritize dual objectives: (1) developing IL-10/TGF-β–promoting therapies to mitigate immune-related adverse events (e.g., retinal vasculitis) and (2) validating LAG-3 + tumor-infiltrating lymphocytes as biomarkers for predicting immune checkpoint inhibitor response in uveal melanoma. Here, IL10 is linked to retinal vasculitis.